602 related articles for article (PubMed ID: 21278246)
1. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.
Konecny GE; Winterhoff B; Kolarova T; Qi J; Manivong K; Dering J; Yang G; Chalukya M; Wang HJ; Anderson L; Kalli KR; Finn RS; Ginther C; Jones S; Velculescu VE; Riehle D; Cliby WA; Randolph S; Koehler M; Hartmann LC; Slamon DJ
Clin Cancer Res; 2011 Mar; 17(6):1591-602. PubMed ID: 21278246
[TBL] [Abstract][Full Text] [Related]
2. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
Logan JE; Mostofizadeh N; Desai AJ; VON Euw E; Conklin D; Konkankit V; Hamidi H; Eckardt M; Anderson L; Chen HW; Ginther C; Taschereau E; Bui PH; Christensen JG; Belldegrun AS; Slamon DJ; Kabbinavar FF
Anticancer Res; 2013 Aug; 33(8):2997-3004. PubMed ID: 23898052
[TBL] [Abstract][Full Text] [Related]
3. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
[TBL] [Abstract][Full Text] [Related]
4. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.
Rivadeneira DB; Mayhew CN; Thangavel C; Sotillo E; Reed CA; Graña X; Knudsen ES
Gastroenterology; 2010 May; 138(5):1920-30. PubMed ID: 20100483
[TBL] [Abstract][Full Text] [Related]
5. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
Finn RS; Dering J; Conklin D; Kalous O; Cohen DJ; Desai AJ; Ginther C; Atefi M; Chen I; Fowst C; Los G; Slamon DJ
Breast Cancer Res; 2009; 11(5):R77. PubMed ID: 19874578
[TBL] [Abstract][Full Text] [Related]
6. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
[TBL] [Abstract][Full Text] [Related]
7. Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.
Vlenterie M; Hillebrandt-Roeffen MH; Schaars EW; Flucke UE; Fleuren ED; Navis AC; Leenders WP; Versleijen-Jonkers YM; van der Graaf WT
Ann Surg Oncol; 2016 Sep; 23(9):2745-52. PubMed ID: 27334220
[TBL] [Abstract][Full Text] [Related]
8. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
[TBL] [Abstract][Full Text] [Related]
9. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
[TBL] [Abstract][Full Text] [Related]
11. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
12. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.
Havrilesky LJ; Alvarez AA; Whitaker RS; Marks JR; Berchuck A
Gynecol Oncol; 2001 Dec; 83(3):491-500. PubMed ID: 11733961
[TBL] [Abstract][Full Text] [Related]
13. PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma.
Barton KL; Misuraca K; Cordero F; Dobrikova E; Min HD; Gromeier M; Kirsch DG; Becher OJ
PLoS One; 2013; 8(10):e77639. PubMed ID: 24098593
[TBL] [Abstract][Full Text] [Related]
14. S-phase lengthening induced by p16(INK4a) overexpression in malignant cells with wild-type pRb and p53.
Chien WW; Domenech C; Catallo R; Salles G; Ffrench M
Cell Cycle; 2010 Aug; 9(16):3286-96. PubMed ID: 20703084
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target.
Ouyang Z; Wang S; Zeng M; Li Z; Zhang Q; Wang W; Liu T
Cell Commun Signal; 2019 Feb; 17(1):17. PubMed ID: 30808351
[TBL] [Abstract][Full Text] [Related]
16. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma.
Willobee BA; Gaidarski AA; Dosch AR; Castellanos JA; Dai X; Mehra S; Messaggio F; Srinivasan S; VanSaun MN; Nagathihalli NS; Merchant NB
Mol Cancer Ther; 2021 Jul; 20(7):1246-1256. PubMed ID: 34001634
[TBL] [Abstract][Full Text] [Related]
17. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy.
McClendon AK; Dean JL; Rivadeneira DB; Yu JE; Reed CA; Gao E; Farber JL; Force T; Koch WJ; Knudsen ES
Cell Cycle; 2012 Jul; 11(14):2747-55. PubMed ID: 22751436
[TBL] [Abstract][Full Text] [Related]
18. Cooperative p16 and p21 action protects female astrocytes from transformation.
Kfoury N; Sun T; Yu K; Rockwell N; Tinkum KL; Qi Z; Warrington NM; McDonald P; Roy A; Weir SJ; Mohila CA; Deneen B; Rubin JB
Acta Neuropathol Commun; 2018 Feb; 6(1):12. PubMed ID: 29458417
[TBL] [Abstract][Full Text] [Related]
19. Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro.
Schrage YM; Lam S; Jochemsen AG; Cleton-Jansen AM; Taminiau AH; Hogendoorn PC; Bovée JV
J Cell Mol Med; 2009 Sep; 13(9A):2843-52. PubMed ID: 18624751
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.
Michaud K; Solomon DA; Oermann E; Kim JS; Zhong WZ; Prados MD; Ozawa T; James CD; Waldman T
Cancer Res; 2010 Apr; 70(8):3228-38. PubMed ID: 20354191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
